HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
HARVARD BIOSCIENCE INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.09+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $36.62M
- P/E (TTM)
- –
- Dividend yield
- –
HARVARD BIOSCIENCE INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instruments, Equipment, Software, and Accessories [Member] | $79.09M | $76.96M | $78.26M | $79.00M | $80.96M | $84.07M | $86.96M | $91.05M | $94.01M | $99.98M | $105.72M | $106.42M | 90.1% | -2.3% |
| Service, Maintenance, and Warranty Contracts [Member] | $8.72M | $8.57M | $8.29M | $8.38M | $7.79M | $7.33M | $7.17M | $6.68M | $7.12M | $6.81M | $6.53M | $6.11M | 9.9% | +11.9% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $38.79M | $37.94M | $38.97M | $38.98M | $39.43M | $40.58M | $41.74M | $43.04M | $45.36M | $46.89M | $48.21M | $48.29M | 44.2% | -1.6% |
| EMEA [Member] | $27.35M | $27.15M | $26.71M | $27.79M | $27.80M | $27.81M | $28.41M | – | – | – | – | – | 31.1% | -1.6% |
| China | $11.67M | $11.04M | $10.97M | $10.48M | $10.97M | $11.77M | $13.30M | – | – | – | – | – | 13.3% | +6.3% |
| Asia, Other [Member] | $6.30M | $6.15M | $6.68M | $6.73M | $7.12M | $7.57M | $7.10M | – | – | – | – | – | 7.2% | -11.5% |
| Americas, Other [Member] | $3.70M | $3.25M | $3.23M | $3.40M | $3.42M | $3.66M | $3.60M | – | – | – | – | – | 4.2% | +8.1% |
| Europe [Member] | – | – | – | – | – | – | – | $28.58M | $29.14M | $31.94M | $32.80M | $32.16M | – | – |
| Rest of the World [Member] | – | – | – | – | – | – | – | $11.08M | $10.85M | $11.29M | $12.76M | $13.17M | – | – |
| Greater China [Member] | – | – | – | – | – | – | $13.30M | $15.03M | $15.78M | $16.67M | $18.49M | $18.90M | – | – |
From the segment and revenue-disaggregation notes of Harvard Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.